Spiriva and Lucentis make France's 100 most reimbursed list
This article was originally published in Scrip
Executive Summary
Just two years after its launch, Boehringer Ingelheim's Spiriva (tiotropium) for chronic obstructive pulmonary disease rose to 40th place last year in the French healthcare insurance programme's list of the top 100 drugs by reimbursement value. Novartis's Lucentis (ranibizumab) appeared in 96th place on the list in its first year of being marketed.